Stomach Cancer News and Research RSS Feed - Stomach Cancer News and Research

Stomach cancer or gastric cancer affects around 7,000 people each year in the UK. Stomach cancer is difficult to detect in the early stages because the initial symptoms are also seen in less serious conditions such as persistent indigestion, heart burn, trapped wind, burping and stomach ache.
Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America. [More]
Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection. [More]
Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu and the Anpac research team are introducing what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published as, "game changing" and "breakthrough" early cancer detection technology research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29 – June 2, 2015. [More]
Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells. [More]
Study: New cases of cancer rising globally, but death rates falling in many countries

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. [More]
New study shows ulcer-causing bacteria can directly interact with stomach stem cells

New study shows ulcer-causing bacteria can directly interact with stomach stem cells

The ulcer-causing bacterium Helicobacter pylori can directly interact with stomach stem cells, causing the cells to divide more rapidly, according to a new study by researchers at the Stanford University School of Medicine. [More]
Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014. [More]
Lightpoint Medical raises $3.1M in Series A financing round for medical imaging technology

Lightpoint Medical raises $3.1M in Series A financing round for medical imaging technology

Lightpoint Medical, a developer of innovative surgical imaging technologies, announced today that the company has raised £2 million ($3.1 million) in a Series A financing round. [More]
Study finds striking gap in cancer survival between countries and regions

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25·7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday). [More]
Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical Services Holdings Limited, an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has received relevant government approvals to establish a free-standing radiotherapy cancer center, Datong Meizhong Jiahe Cancer Center ("Datong Center") in Datong City, Shanxi Province. [More]
Blocking nerve signals could be effective treatment for stomach cancer

Blocking nerve signals could be effective treatment for stomach cancer

Research from Columbia University Medical Center shows that nerves may play a critical role in stomach cancer growth and that blocking nerve signals using surgery or Botox® (onabotulinumtoxinA) could be an effective treatment for the disease. [More]
Microbes influence human eating behavior, dietary choices

Microbes influence human eating behavior, dietary choices

It sounds like science fiction, but it seems that bacteria within us — which outnumber our own cells about 100-fold — may very well be affecting both our cravings and moods to get us to eat what they want, and often are driving us toward obesity. [More]
Research: New protein complex fights against bacterial infection that causes gastric cancer

Research: New protein complex fights against bacterial infection that causes gastric cancer

New study by Cancer Science Institute of Singapore at NUS show that the protein is produced as an immune response and requires the tumour suppressor RUNX3. [More]
Scientists develop magnetic bacteria that may help diagnose digestive diseases like stomach cancer

Scientists develop magnetic bacteria that may help diagnose digestive diseases like stomach cancer

Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer. [More]
Vaccine against H. pylori infection is within reach

Vaccine against H. pylori infection is within reach

Researchers from the University of Rhode Island are championing a recent breakthrough in the laboratory with hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and to therapeutics for inflammatory diseases. [More]
FDA approves Cyramza to treat patients with advanced stomach cancer

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
Researchers provide new blood test for early detection of stomach cancer

Researchers provide new blood test for early detection of stomach cancer

University of Adelaide research has provided new hope for the early detection of stomach cancer with the identification of four new biomarkers in the blood of human cancer patients. [More]
Advertisement
Advertisement